La chaîne d'options affiche les données clés des options sur actions de Intelligent Bio Solutions à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Intelligent Bio Solutions..

Intelligent Bio Solutions (NASDAQ:INBS) Stock, Chaîne d'Options

Intelligent Bio Solutions

Intelligent Bio Solutions Inc is a life sciences company developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. Its Biosensor Platform is developing and launching diagnostic tests urgently needed to help people living with chronic diseases. It also engages in the advancement of portable drug abuse testing through the analysis of fingerprint sweat. The test is non-invasive, hygienic, and fast, and screens for recent use of opioids, cocaine, methamphetamines, benzodiazepines, and marijuana. The company business through two operating segments include Commercially available Intelligent Fingerprinting Products (IFPG or IFPG segment) and, Development Stage Biosensor Platform Technology (BPT segment).

Intelligent Bio Solutions Inc. - Common Stock

Intelligent Bio Solutions Inc

BMO Capital analyst Keith Bachman maintains Okta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKTA#NASDAQ">OKTA</a>) with a Market Perform and raises the price target from $130 to $135.

News

Price Target

Analyst Ratings

OKTA

BMO Capital Maintains Market Perform on Okta, Raises Price Target to $135

BMO Capital analyst James Thalacker maintains NRG Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRG#NYSE">NRG</a>) with a Market Perform and raises the price target from $115 to $167.

BMO Capital Maintains Market Perform on NRG Energy, Raises Price Target to $167

BMO Capital analyst Keith Bachman maintains ServiceNow (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>) with a Outperform and raises the price target from $1025 to $1150.

BMO Capital Maintains Outperform on ServiceNow, Raises Price Target to $1150

WIIM

Millrose Properties shares are trading higher after the company reported Q1 financial results and raised its FY25 guidance for new transaction funding outside of the Lennar Master program.

Trading Ideas

JOET

iShares Trust Barclays 20+ Year Treasury Bond Fund

Live On CNBC, Joe Terranova Announces Sold Entire iShares 20+ Year Treasury Bond ETF Position

WING

Wingstop shares are trading higher after multiple firms raised their respective price targets on the stock.

Shares of Under Armour Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UAA#NYSE">UAA</a>) were declining in early trading on Wednesday, after the company Tuesday reported its <a href="https://www.benzinga.com/25/05/45383247/under-armour-tops-q4-sales-estimates-details-here">fiscal fourth-quarter results</a>.
Here are some key analyst takeaways.
<ul class="wp-block-list">
<li>Truist Securities <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/655796fc7f07f10001c9da96/joseph-civello">analyst Joseph Civello</a> reaffirmed a Buy rating, while reducing the price target from $9 to $7.</li>
<li>Stifel <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58beb7e7b85e93000190633d/jim-duffy">analyst Jim Duffy</a> maintained a Buy rating, while cutting the price target from $11 to $10.</li>
<li>Needham <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5846ee56ee7bf6000154d12e/tom-nikic">analyst Tom Nikic</a> reiterated a Hold rating on the stock.</li>
</ul>
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
Truist Securities: Under Armour reported its fiscal fourth-quarter results broadly in line with expectations while providing mixed guidance. Lower promotions led to gross margin expansion, he added.
The company projected sales to decline by 4%-5% in the fiscal first quarter, coming in well below the prior consensus estimate of 1.6% growth, the analyst stated. "While we believe the company's efforts to elevate the brand's positioning are prudent, tariff-driven uncertainty makes us incrementally cautious on their ability to drive full-priced demand higher," he further wrote.
Stifel: Under Armour reported quarterly revenue of $1.18 billion, slightly above consensus of $1.16 billion, Duffy said. Gross margin expanded by 170 basis points to 46.7%, beating Street's 46.0% estimates, he added.
The company's year-on-year improvement was driven by "supply chain benefits including lower product and freight costs, favorable pricing, and positive impacts from product mix and FX, partially offset by an unfavorable channel and regional mix," the analyst wrote. Management guided to adjusted earnings of 1-3 cents per share for the fiscal first quarter, better than the Street's prior breakeven estimate, he further stated.
Needham: Under Armour's results were marginally better than expected, although its revenues are yet to bottom, Nikic said. With the company lowering discounts, revenues declined again, following an almost 10% downturn last year, he added.
The analyst stated that it is yet to be seen whether Under Armour's upcoming product seasons will "bear fruit on the top line. &#8221; Management expects revenue to decline 4%- 5% in the fiscal first quarter.
UAA Price Action: Shares of Under Armour had declined by 0.56% to $6.24 at the time of publication on Wednesday.
Read More: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/05/45262278/under-armour-faces-tough-road-ahead-says-analyst">Under Armour Faces Tough Road Ahead, Says Analyst</a></li>
</ul>
Image: Shutterstock

Analyst Color

Earnings

Reiteration

Under Armour Finds No Major Surprises In Q4, Analysts Cut Price Target

IPOs

ETOR

Etoro Group IPO Opens For Trade At $69.69/Share; IPO Priced At $52/Share On 11,923,018 Shares

B. Riley Securities analyst Josh Nichols maintains Nayax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NYAX#NASDAQ">NYAX</a>) with a Buy and raises the price target from $44 to $47.

NYAX

B. Riley Securities Maintains Buy on Nayax, Raises Price Target to $47

B. Riley Securities analyst Josh Nichols maintains 8x8 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EGHT#NASDAQ">EGHT</a>) with a Buy and lowers the price target from $4 to $3.

EGHT

B. Riley Securities Maintains Buy on 8x8, Lowers Price Target to $3

B. Riley Securities analyst David Bain maintains DoubleDown Interactive Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DDI#NASDAQ">DDI</a>) with a Buy and lowers the price target from $23 to $22.

B. Riley Securities Maintains Buy on DoubleDown Interactive Co, Lowers Price Target to $22

CyberArk Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYBR#NASDAQ">CYBR</a>) has outperformed the market over the past 10 years by 8.23% on an annualized basis producing an average annual return of 18.92%. Currently, CyberArk Software has a market capitalization of $17.62 billion. 
Buying $1000 In CYBR: If an investor had bought $1000 of CYBR stock 10 years ago, it would be worth $5,650.80 today based on a price of $357.54 for CYBR at the time of writing.
<h3>CyberArk Software's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747239479_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CYBR

Here's How Much You Would Have Made Owning CyberArk Software Stock In The Last 10 Years

B. Riley Securities analyst Craig Ellis maintains Camtek (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAMT#NASDAQ">CAMT</a>) with a Buy and raises the price target from $85 to $95.

CAMT

B. Riley Securities Maintains Buy on Camtek, Raises Price Target to $95

Shares of Aurora Innovation Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUR#NASDAQ">AUR</a>) are trading lower by 8.81% to $6.67 during Wednesday&#8217;s session after Uber Technologies Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>) announced plans to monetize part of its stake in the autonomous vehicle company through a $1 billion <a href="https://www.benzinga.com/news/offerings/25/05/45393539/aurora-innovation-stock-drops-after-the-bell-whats-going-on">convertible note offering</a>.
What To Know: According to an <a href="https://www.benzinga.com/pressreleases/25/05/b45397128/uber-announces-pricing-of-1-0-billion-exchangeable-senior-notes-offering">SEC filing</a>, Uber will privately place senior notes due 2028 with institutional investors. The zero-coupon notes will be exchangeable for Aurora common stock at an initial exchange price of approximately $8.50 per share. The offering includes an option for an additional $150 million in notes and is expected to close on May 20.
Uber <a href="https://www.benzinga.com/news/offerings/25/05/45393539/aurora-innovation-stock-drops-after-the-bell-whats-going-on">acquired</a> its Aurora stake in 2020 when it sold its self-driving unit to the company in an all-equity deal worth $400 million, securing a 26% ownership. CEO Dara Khosrowshahi, who joined Aurora's board as part of the deal, plans to step down by year-end.
The notes will be secured by Uber's Aurora shares through its subsidiary Neben Holdings. Uber expects to use the net proceeds, anticipated at around $979 million, for general corporate purposes, potentially including strategic investments.
Read Also: <a href="https://www.benzinga.com/news/25/05/45408806/zevra-therapeutics-zvra-stock-jumps-on-strong-q1-results-whats-going-on">Zevra Therapeutics Stock Jumps on Strong Q1 Results: What&#8217;s Going On?</a>
<h2 class="wp-block-heading">How To Buy AUR Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Aurora Innovation&#8217;s case, it is in the Information Technology sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, AUR has a 52-week high of $10.77 and a 52-week low of $2.10.
Photo: courtesy of Aurora Innovation.

Movers

UBER

Aurora Innovation Shares Fall As Uber Announces $1B Note Offering: What's Going On?

Truist Securities analyst Nicole Germino maintains Y-mAbs Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YMAB#NASDAQ">YMAB</a>) with a Buy and lowers the price target from $18 to $14.

YMAB

Truist Securities Maintains Buy on Y-mAbs Therapeutics, Lowers Price Target to $14

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 100 points on Wednesday.
The Dow traded up 0.08% to 42,172.43 while the NASDAQ gained 0.74% to 19,151.42. The S&amp;P 500 also rose, gaining, 0.24% to 5,900.93.
Check This Out: <a href="https://www.benzinga.com/25/05/45402795/top-3-materials-stocks-that-could-blast-off-this-month">Top 3 Materials Stocks That Could Blast Off This Month</a>
Leading and Lagging Sectors Communication services shares jumped by 1.6% on Wednesday.
In trading on Wednesday, health care stocks fell by 1.4%.
Top Headline
U.S. crude oil inventories increased by 3.454 million barrels in the week ended May 9, compared to market estimates of a 1 million barrel decline.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul class="wp-block-list">
<li>Incannex Healthcare Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IXHL#NASDAQ">IXHL</a>) shares shot up 672% to $0.6586 after the company completed patient dosing in the Phase 2 portion of its Phase 2/3 RePOSA study of IHL-42X for obstructive sleep apnea.</li>
<li>Shares of Septerna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEPN#NASDAQ">SEPN</a>) got a boost, surging 44% to $9.71 after the company announced an exclusive global collaboration and license agreement with Novo Nordisk to develop oral small molecule medicines for obesity, type 2 diabetes, and other cardiometabolic diseases.</li>
<li>Nutex Health Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUTX#NASDAQ">NUTX</a>) shares were also up, gaining 25% to $157.12 after the company reported better-than-expected first-quarter financial results.</li>
</ul>
Equities Trading DOWN
<ul class="wp-block-list">
<li>Global-E Online Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLBE#NASDAQ">GLBE</a>) shares dropped 15% to $36.12 following first-quarter results.</li>
<li>Shares of Cellebrite DI Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLBT#NASDAQ">CLBT</a>) were down 11% to $17.82 after the company reported mixed first-quarter financial results and cut its FY25 sales guidance with its midpoint below estimates. Also, the company issued second-quarter sales guidance with its midpoint below estimates.</li>
<li>Loar Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOAR#NYSE">LOAR</a>) was down, falling 8% to $86.20 after the company launched a secondary public offering consisting of 9 million shares.</li>
</ul>
Commodities In commodity news, oil traded down 0.5% to $63.33 while gold traded down 1.9% at $3,186.40.
Silver traded down 2% to $32.440 on Wednesday, while copper fell 1.4% to $4.6550.
Euro zone
European shares were mostly lower today. The eurozone's STOXX 600 fell 0.24%, while Spain's IBEX 35 Index rose 0.52%. London's FTSE 100 slipped 0.21%, Germany's DAX 40 fell 0.47% and France's CAC 40 slipped 0.47% during the session.
Asia Pacific Markets
Asian markets closed mostly higher on Wednesday, with Japan's Nikkei falling 0.14%, Hong Kong's Hang Seng Index gaining 2.30%, China's Shanghai Composite Index gaining 0.86% and India's BSE Sensex gaining 0.22%.
Economics
<ul class="wp-block-list">
<li>U.S. mortgage application volumes increased by 1.1% from the previous week in the week ending May 9, following an 11% surge in the prior period.</li>
<li>U.S. crude oil inventories increased by 3.454 million barrels in the week ended May 9, compared to market estimates of a 1 million barrel decline.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/05/45375319/jim-cramer-ok-harrow-recommends-buying-this-energy-stock">Jim Cramer Is &#8216;OK&#8217; With Harrow, Recommends Buying This Energy Stock</a> </li>
</ul>
Photo via Shutterstock

Equities

Eurozone

Commodities

Intraday Update

Markets

CLBT

GLBE

IXHL

LOAR

NUTX

SEPN

Dow Edges Higher; US Crude Oil Inventories Increase

Truist Securities analyst Joseph Civello maintains Under Armour (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UAA#NYSE">UAA</a>) with a Hold and lowers the price target from $9 to $7.

Truist Securities Maintains Hold on Under Armour, Lowers Price Target to $7

Truist Securities analyst Nicole Germino maintains Perspective Therapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CATX#AMEX">CATX</a>) with a Buy and lowers the price target from $10 to $8.

CATX

Truist Securities Maintains Buy on Perspective Therapeutics, Lowers Price Target to $8

Rumors

Etoro Group IPO Price Indicating $69.50 On 1.2M Shares; IPO Priced At $52/Share On 11,923,018 Shares

Truist Securities analyst Mark Hughes maintains PennantPark Floating Rate (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFLT#NYSE">PFLT</a>) with a Buy and lowers the price target from $12 to $11.

Comments

Intelligent Bio Solutions

Intelligent Bio Solutions (INBS) Options

No option chain data available. Please try again later

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL